CX Stock Analysis: Cemex SAB de CV | NYSE
Building Materials | NYSE, USA | Market Cap: 17.474m USD | 12M Return: 70.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 53.5M
EPS Trend: 64.0%
Qual. Beats: 0
Rev. Trend: -57.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CEMEX (NYSE: CX) is a Mexico-based global building materials company that produces, markets, distributes, and sells cement, ready-mix concrete, aggregates, and related urbanization solutions and construction services. Its product portfolio spans gray, white, and blended cements, a wide range of specialty ready-mix concretes, crushed stone, gravel, and manufactured sand, as well as the Vertua line of lower-carbon products and construction chemicals, mortars, and asphalt offerings. The company also provides waste management solutions for municipal, industrial, construction, and demolition streams.
Founded in 1906 and headquartered in San Pedro Garza García, Mexico, CEMEX trades on the NYSE as an ADR (ticker CX) following its 1999 listing and is classified within the GICS Materials sector, Construction Materials sub-industry. The vertically integrated cement-to-concrete-to-aggregates model is characteristic of large building materials producers and typically exposes the business to infrastructure and residential/commercial construction cycles, while cement manufacturing is capital- and energy-intensive, making scale and geographic diversification key competitive levers.
- US housing and infrastructure demand drives cement volumes
- Energy and fuel costs pressure cement producer margins
- Mexico peso volatility impacts reported earnings and debt servicing
| Net Income: 456.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.73 > 1.0 |
| NWC/Revenue: -5.30% < 20% (prev -5.28%; Δ -0.02% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.35b > Net Income 456.6m |
| Net Debt (7.85b) to EBITDA (2.69b): 2.92 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (146.3m) vs 12m ago -89.92% < -2% |
| Gross Margin: 31.83% > 18% (prev 32.32%; Δ -0.48% > 0.5%) |
| Asset Turnover: 59.04% > 50% (prev 56.61%; Δ 2.43% > 0%) |
| Interest Coverage Ratio: 2.71 > 6 (EBIT TTM 1.38b / Interest Expense TTM 510.0m) |
| A: -0.03 (Total Current Assets 5.64b - Total Current Liabilities 6.52b) / Total Assets 28.1b |
| B: 0.22 (Retained Earnings 6.12b / Total Assets 28.1b) |
| C: 0.05 (EBIT TTM 1.38b / Avg Total Assets 28.0b) |
| D: 0.90 (Book Value of Equity 13.1b / Total Liabilities 14.7b) |
| Altman-Z'' = 1.78 = BBB |
| DSRI: 1.11 (Receivables 2.89b/2.50b, Revenue 16.6b/15.8b) |
| GMI: 1.02 (GM 32.32% / 31.83%) |
| AQI: 0.94 (AQ_t 0.37 / AQ_t-1 0.40) |
| SGI: 1.05 (Revenue 16.6b / 15.8b) |
| TATA: -0.07 (NI 456.6m - CFO 2.35b) / TA 28.1b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of July 13, 2026, the stock is trading at USD 12.48 with a total of 4,055,505 shares traded. Over the past week, the price has changed by +1.55%, over one month by -3.62%, over three months by +5.21% and over the past year by +70.60%.
Current recommended Stop Loss: 11.90 (which is 4.6% or 1.5 ATR below the current price).
Cemex SAB de CV has received a consensus analysts rating of 3.87. Therefore, it is recommended to buy CX.
- StrongBuy: 3
- Buy: 7
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.4 | 15.5% |
P/E Trailing = 34.6
P/E Forward = 15.873
P/S = 1.0567
P/B = 1.3499
P/EG = 0.3877
Revenue TTM = 16.6b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 2.69b USD
Long Term Debt = 4.76b USD (from longTermDebt, last quarter)
Short Term Debt = 476.7m USD (from shortTermDebt, last quarter)
Debt = 8.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.08b
Net Debt = 7.85b USD (calculated: Debt 8.54b - CCE 687.0m)
Enterprise Value = 25.3b USD (17.5b + Debt 8.54b - CCE 687.0m)
Interest Coverage Ratio = 2.71 (Ebit TTM 1.38b / Interest Expense TTM 510.0m)
EV/FCF = 18.54x (Enterprise Value 25.3b / FCF TTM 1.37b)
FCF Yield = 5.39% (FCF TTM 1.37b / Enterprise Value 25.3b)
FCF Margin = 8.25% (FCF TTM 1.37b / Revenue TTM 16.6b)
Net Margin = 2.76% (Net Income TTM 456.6m / Revenue TTM 16.6b)
Gross Margin = 31.83% ((Revenue TTM 16.6b - Cost of Revenue TTM 11.3b) / Revenue TTM)
Gross Margin QoQ = 32.85% (prev 26.96%)
Tobins Q-Ratio = 0.90 (Enterprise Value 25.3b / Total Assets 28.1b)
Interest Expense / Debt = 5.97% (Interest Expense 510.0m / Debt 8.54b)
Taxrate = 45.47% (428.7m / 942.7m)
NOPAT = 754.8m (EBIT 1.38b * (1 - 45.47%))
Current Ratio = 0.87 (Total Current Assets 5.64b / Total Current Liabilities 6.52b)
Debt / Equity = 0.65 (Debt 8.54b / totalStockholderEquity, last quarter 13.1b)
Debt / EBITDA = 2.92 (Net Debt 7.85b / EBITDA 2.69b)
Debt / FCF = 5.75 (Net Debt 7.85b / FCF TTM 1.37b)
Total Stockholder Equity = 13.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.63% (Net Income 456.6m / Total Assets 28.1b)
RoE = 3.42% (Net Income TTM 456.6m / Total Stockholder Equity 13.4b)
RoCE = 7.64% (EBIT 1.38b / Capital Employed (Equity 13.4b + L.T.Debt 4.76b))
RoIC = 3.53% (NOPAT 754.8m / Invested Capital 21.4b)
WACC = 7.93% (E(17.5b)/V(26.0b) * Re(10.21%) + D(8.54b)/V(26.0b) * Rd(5.97%) * (1-Tc(0.45)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -26.97 | Cagr: -63.91%
[DCF] Terminal Value 77.97% ; FCFF base≈1.17b ; Y1≈1.34b ; Y5≈1.97b
[DCF] Fair Price = 15.14 (EV 29.7b - Net Debt 7.85b = Equity 21.8b / Shares 1.44b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 63.98 | EPS CAGR: 19.17% | SUE: 0.36 | # QB: 0
Revenue Correlation: -57.53 | Revenue CAGR: -1.68% | SUE: 0.62 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.18 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.81 | Chg30d=+1.89% | Revisions=+0% | GrowthEPS=+55.7% | GrowthRev=+7.3%
EPS next Year (2027-12-31): EPS=0.90 | Chg30d=+1.35% | Revisions=-25% | GrowthEPS=+11.4% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -17% (up=1, down=2)